文献速递垂体与肾上腺疾病性腺与生殖内分泌

经典21-羟化酶缺陷症患儿肾上腺功能初现期及之后的身高生长特征

Characteristics of Growth in Children With Classic Congenital Adrenal Hyperplasia due to 21-Hydroxylase Deficiency During Adrenarche and Beyond.
PubMed 文献 · J Clin Endocrinol Metab · 2022-01-01

这项回顾性多中心研究纳入41例1990-2012年出生的经典先天性肾上腺皮质增生症(CAH)患者,分析肾上腺功能初现期生长对最终身高的影响。患者最终身高低于同龄人(-0.4 SDS)及父母(校正最终身高-0.6 SDS)。肾上腺功能初现期存在骨龄加速(49%)与未加速两种模式,骨龄加速者当时身高较高但预测成年身高较低;然而青春期复评时两组最终(预测)身高相似。骨龄不应单独作为肾上腺功能初现期CAH代谢控制的临床指标。

要点

  • 经典CAH患者最终身高低于同龄人及父母。
  • 肾上腺功能初现期骨龄加速者当时身高较高但预测成年身高较低。
  • 青春期复评时骨龄加速与未加速组最终(预测)身高相似。

核心结论

  • 肾上腺功能初现期骨龄加速与未加速的经典CAH患者,在青春期复评时最终(预测)身高相似。
  • 骨龄不应在肾上腺功能初现期单独作为CAH代谢控制的临床指标。

研究设计与样本

  • 回顾性多中心研究,纳入4个学术性儿科内分泌中心的41例经典CAH患者,出生年份为1990-2012年。
  • 评估骨龄、生长速度及(预测)成年身高结局,并分析性别、基因型及糖皮质激素治疗等影响因素。

主要发现

  • 经典CAH患者身高较同龄人低(-0.4 SDS ± 0.8 SD),较父母校正最终身高低(-0.6 SDS ± 1.0 SD)。
  • 肾上腺功能初现期49%患者骨龄相对实际年龄加速(BA-CA加速),其余未加速。
  • 骨龄加速者在肾上腺功能初现期身高高于正常人群(P = 0.001),但预测成年身高SDS较低(-0.9 SDS [95% CI, -1.3; -0.5]),而未加速者为0.2 SDS [95% CI, -0.3; 0.8]。
  • 最终成年身高在骨龄加速组与未加速组均降低且相似(-0.4 SDS [95% CI, -0.9; 0.1] vs -0.3 SDS [95% CI, -0.8; 0.1])。

临床怎么用

  • 临床不应在肾上腺功能初现期单独依据骨龄评估CAH代谢控制。
  • 对经典CAH患者需持续监测生长与骨龄,但需结合其他指标综合判断。

局限性

  • 回顾性研究设计。
  • 样本量较小(41例)。
  • 仅纳入4个中心,可能存在选择偏倚。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

CONTEXT: Patients with classic congenital adrenal hyperplasia (CAH) often do not achieve their full growth potential. Adrenarche may accelerate bone maturation and thereby result in decreased growth in CAH. OBJECTIVE: The study aimed to analyze the impact of growth during adrenarche on final height of adequately treated classic CAH patients. METHODS: This retrospective, multicenter study (4 academic pediatric endocrinology centers) included 41 patients with classical CAH, born 1990-2012. We assessed skeletal maturation (bone age), growth velocity, and (projected) adult height outcomes, and analyzed potential influencing factors, such as sex, genotype, and glucocorticoid therapy. RESULTS: Patients with classic CAH were shorter than peers (-0.4 SDS ± 0.8 SD) and their parents (corrected final height -0.6 SDS ± 1.0 SD). Analysis of growth during adrenarche revealed 2 different growth patterns: patients with accelerating bone age (49%), and patients with nonaccelerating bone age relative to chronological age (BA-CA). Patients with accelerating BA-CA were taller than the normal population during adrenarche years (P = 0.001) and were predicted to achieve lower adult height SDS (-0.9 SDS [95% CI, -1.3; -0.5]) than nonaccelerating patients when assessed during adrenarche (0.2 SDS [95% CI, -0.3; 0.8]). Final adult height was similarly reduced in both accelerating and nonaccelerating BA-CA groups (-0.4 SDS [95% CI, -0.9; 0.1] vs -0.3 SDS [95% CI, [-0.8; 0.1]). CONCLUSION: Patients with and without significant bone age advancement, and thus differing height prediction during adrenarche, showed similar (predicted) final height when reassessed during pubertal years. Bone age alone should not be used during adrenarche as clinical marker for metabolic control in CAH treatment.

来源:J Clin Endocrinol Metab,查看原文。版权归原作者所有。

引用

  1. Troger T, Sommer G, Lang-Muritano M, et al. Characteristics of Growth in Children With Classic Congenital Adrenal Hyperplasia due to 21-Hydroxylase Deficiency During Adrenarche and Beyond. J Clin Endocrinol Metab. 2022. PMID: 34599587. doi:10.1210/clinem/dgab701

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。